188 related articles for article (PubMed ID: 36163066)
1. Gasdermin B over-expression modulates HER2-targeted therapy resistance by inducing protective autophagy through Rab7 activation.
Gámez-Chiachio M; Molina-Crespo Á; Ramos-Nebot C; Martinez-Val J; Martinez L; Gassner K; Llobet FJ; Soriano M; Hernandez A; Cordani M; Bernadó-Morales C; Diaz E; Rojo-Sebastian A; Triviño JC; Sanchez L; Rodríguez-Barrueco R; Arribas J; Llobet-Navás D; Sarrió D; Moreno-Bueno G
J Exp Clin Cancer Res; 2022 Sep; 41(1):285. PubMed ID: 36163066
[TBL] [Abstract][Full Text] [Related]
2. Intracellular Delivery of an Antibody Targeting Gasdermin-B Reduces HER2 Breast Cancer Aggressiveness.
Molina-Crespo Á; Cadete A; Sarrio D; Gámez-Chiachio M; Martinez L; Chao K; Olivera A; Gonella A; Díaz E; Palacios J; Dhal PK; Besev M; Rodríguez-Serrano M; García Bermejo ML; Triviño JC; Cano A; García-Fuentes M; Herzberg O; Torres D; Alonso MJ; Moreno-Bueno G
Clin Cancer Res; 2019 Aug; 25(15):4846-4858. PubMed ID: 31064780
[TBL] [Abstract][Full Text] [Related]
3. Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer.
Hergueta-Redondo M; Sarrio D; Molina-Crespo Á; Vicario R; Bernadó-Morales C; Martínez L; Rojo-Sebastián A; Serra-Musach J; Mota A; Martínez-Ramírez Á; Castilla MÁ; González-Martin A; Pernas S; Cano A; Cortes J; Nuciforo PG; Peg V; Palacios J; Pujana MÁ; Arribas J; Moreno-Bueno G
Oncotarget; 2016 Aug; 7(35):56295-56308. PubMed ID: 27462779
[TBL] [Abstract][Full Text] [Related]
4. HO-1 drives autophagy as a mechanism of resistance against HER2-targeted therapies.
Tracey N; Creedon H; Kemp AJ; Culley J; Muir M; Klinowska T; Brunton VG
Breast Cancer Res Treat; 2020 Feb; 179(3):543-555. PubMed ID: 31705351
[TBL] [Abstract][Full Text] [Related]
5. Gasdermin-B promotes invasion and metastasis in breast cancer cells.
Hergueta-Redondo M; Sarrió D; Molina-Crespo Á; Megias D; Mota A; Rojo-Sebastian A; García-Sanz P; Morales S; Abril S; Cano A; Peinado H; Moreno-Bueno G
PLoS One; 2014; 9(3):e90099. PubMed ID: 24675552
[TBL] [Abstract][Full Text] [Related]
6. Regulation of cell survival by HUNK mediates breast cancer resistance to HER2 inhibitors.
Yeh ES; Abt MA; Hill EG
Breast Cancer Res Treat; 2015 Jan; 149(1):91-8. PubMed ID: 25515931
[TBL] [Abstract][Full Text] [Related]
7. Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment.
Cufí S; Vazquez-Martin A; Oliveras-Ferraros C; Corominas-Faja B; Urruticoechea A; Martin-Castillo B; Menendez JA
Oncotarget; 2012 Dec; 3(12):1600-14. PubMed ID: 23307622
[TBL] [Abstract][Full Text] [Related]
8. A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression.
Lee J; Bartholomeusz C; Mansour O; Humphries J; Hortobagyi GN; Ordentlich P; Ueno NT
Breast Cancer Res Treat; 2014 Jul; 146(2):259-72. PubMed ID: 24916181
[TBL] [Abstract][Full Text] [Related]
9. Her2-Targeted Therapy Induces Autophagy in Esophageal Adenocarcinoma Cells.
Janser FA; Adams O; Bütler V; Schläfli AM; Dislich B; Seiler CA; Kröll D; Langer R; Tschan MP
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30297650
[TBL] [Abstract][Full Text] [Related]
10. Phosphoproteomic analysis reveals PAK2 as a therapeutic target for lapatinib resistance in HER2-positive breast cancer cells.
Chang Y; Park KH; Lee JE; Han KC
Biochem Biophys Res Commun; 2018 Oct; 505(1):187-193. PubMed ID: 30243723
[TBL] [Abstract][Full Text] [Related]
11. Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation.
Wang YC; Morrison G; Gillihan R; Guo J; Ward RM; Fu X; Botero MF; Healy NA; Hilsenbeck SG; Phillips GL; Chamness GC; Rimawi MF; Osborne CK; Schiff R
Breast Cancer Res; 2011; 13(6):R121. PubMed ID: 22123186
[TBL] [Abstract][Full Text] [Related]
12. Gasdermin-B Pro-Tumor Function in Novel Knock-in Mouse Models Depends on the
Sarrio D; Rojo-Sebastián A; Teijo A; Pérez-López M; Díaz-Martín E; Martínez L; Morales S; García-Sanz P; Palacios J; Moreno-Bueno G
Front Cell Dev Biol; 2022; 10():813929. PubMed ID: 35281099
[TBL] [Abstract][Full Text] [Related]
13. Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation.
Fernández-Nogueira P; Mancino M; Fuster G; López-Plana A; Jauregui P; Almendro V; Enreig E; Menéndez S; Rojo F; Noguera-Castells A; Bill A; Gaither LA; Serrano L; Recalde-Percaz L; Moragas N; Alonso R; Ametller E; Rovira A; Lluch A; Albanell J; Gascon P; Bragado P
Clin Cancer Res; 2020 Mar; 26(6):1432-1448. PubMed ID: 31699826
[TBL] [Abstract][Full Text] [Related]
14. RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer.
Sanz-Moreno A; Palomeras S; Pedersen K; Morancho B; Pascual T; Galván P; Benítez S; Gomez-Miragaya J; Ciscar M; Jimenez M; Pernas S; Petit A; Soler-Monsó MT; Viñas G; Alsaleem M; Rakha EA; Green AR; Santamaria PG; Mulder C; Lemeer S; Arribas J; Prat A; Puig T; Gonzalez-Suarez E
Breast Cancer Res; 2021 Mar; 23(1):42. PubMed ID: 33785053
[TBL] [Abstract][Full Text] [Related]
15. Protective autophagy promotes the resistance of HER2-positive breast cancer cells to lapatinib.
Chen S; Zhu X; Qiao H; Ye M; Lai X; Yu S; Ding L; Wen A; Zhang J
Tumour Biol; 2016 Feb; 37(2):2321-31. PubMed ID: 26369543
[TBL] [Abstract][Full Text] [Related]
16. HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2
Xu X; De Angelis C; Burke KA; Nardone A; Hu H; Qin L; Veeraraghavan J; Sethunath V; Heiser LM; Wang N; Ng CKY; Chen ES; Renwick A; Wang T; Nanda S; Shea M; Mitchell T; Rajendran M; Waters I; Zabransky DJ; Scott KL; Gutierrez C; Nagi C; Geyer FC; Chamness GC; Park BH; Shaw CA; Hilsenbeck SG; Rimawi MF; Gray JW; Weigelt B; Reis-Filho JS; Osborne CK; Schiff R
Clin Cancer Res; 2017 Sep; 23(17):5123-5134. PubMed ID: 28487443
[No Abstract] [Full Text] [Related]
17. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
Park SH; Ito K; Olcott W; Katsyv I; Halstead-Nussloch G; Irie HY
Breast Cancer Res; 2015 Jun; 17(1):86. PubMed ID: 26084280
[TBL] [Abstract][Full Text] [Related]
18. Targeting the EphB4 receptor tyrosine kinase sensitizes HER2-positive breast cancer cells to Lapatinib.
Ding J; Yao Y; Huang G; Wang X; Yi J; Zhang N; Liu C; Wang K; Zhang Y; Wang M; Liu P; Ye M; Li M; Cheng H
Cancer Lett; 2020 Apr; 475():53-64. PubMed ID: 32006616
[TBL] [Abstract][Full Text] [Related]
19. NF-κB activation-induced anti-apoptosis renders HER2-positive cells drug resistant and accelerates tumor growth.
Bailey ST; Miron PL; Choi YJ; Kochupurakkal B; Maulik G; Rodig SJ; Tian R; Foley KM; Bowman T; Miron A; Brown M; Iglehart JD; Debajit KB
Mol Cancer Res; 2014 Mar; 12(3):408-420. PubMed ID: 24319068
[TBL] [Abstract][Full Text] [Related]
20. HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2.
Hanker AB; Garrett JT; Estrada MV; Moore PD; Ericsson PG; Koch JP; Langley E; Singh S; Kim PS; Frampton GM; Sanford E; Owens P; Becker J; Groseclose MR; Castellino S; Joensuu H; Huober J; Brase JC; Majjaj S; Brohée S; Venet D; Brown D; Baselga J; Piccart M; Sotiriou C; Arteaga CL
Clin Cancer Res; 2017 Aug; 23(15):4323-4334. PubMed ID: 28381415
[No Abstract] [Full Text] [Related]
[Next] [New Search]
